Needham & Company Assumes Coverage on Pharmacyclics (PCYC) at Buy; Review and ASH Meeting Preview

Needham & Company assumes coverage on Pharmacyclics (NASDAQ: PCYC) with a Buy. PT $14.00.

Needham analyst says, "Pharmacyclics is developing PCI-32765, a small molecule Btk inhibitor, for the treatment of B-cell related cancers. Data from a collection of open-label Phase 1/2 trials have pointed to impressive efficacy as well as an encouraging safety profile. The company is focusing initially on relapsed/refractory (r/r) Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL), with plans to ultimately expand to a broader front-line Non-Hodgkin’s Lymphoma label."

For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.

Shares of Pharmacyclics closed at $11.10 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Lake Street Capital Markets Starts Research Solutions Inc. (RSSS) at Buy
• Leerink Partners Starts Cartesian Therapeutics (RNAC) at Outperform
• Needham Starts Viavi Solutions (VIAV) at Hold